Lord, Abbett & Co. LLC Krystal Biotech, Inc. Transaction History
Lord, Abbett & Co. LLC
- $31.6 Billion
- Q4 2024
A detailed history of Lord, Abbett & Co. LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Lord, Abbett & Co. LLC holds 215,628 shares of KRYS stock, worth $33.6 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
215,628
Previous 284,159
24.12%
Holding current value
$33.6 Million
Previous $51.7 Million
34.69%
% of portfolio
0.11%
Previous 0.16%
Shares
29 transactions
Others Institutions Holding KRYS
# of Institutions
308Shares Held
24.5MCall Options Held
506KPut Options Held
383K-
Black Rock Inc. New York, NY3.95MShares$615 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$448 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.63MShares$409 Million6.0% of portfolio
-
State Street Corp Boston, MA1.28MShares$199 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$154 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...